Veloxis Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference

Feb 09, 2012, 08:00 ET from Veloxis Pharmaceuticals A/S

HORSHOLM, Denmark, Feb. 9, 2012 /PRNewswire/ -- William J. Polvino M.D president and CEO of Veloxis Pharmaceuticals A/S, will present at the 14th Annual BIO CEO & Investor Conference at 3 p.m. EST, Tuesday, Feb. 14, at The Waldorf-Astoria in New York. Dr. Polvino will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis' candidate to prevent organ transplant rejection. 

About Veloxis Pharmaceuticals A/S

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.

For further information, please visit

For U.S. investor and media contacts:

John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
(732) 321-3208

SOURCE Veloxis Pharmaceuticals A/S